BenzingaAugust 11, 2026 at 5:51 AM NY2 Months Ago
Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710
Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
